@article{336,
  author = {Anh Bui and Christina Kong and Nicole Kelly and S Rathinam and John Gonzales and Radhika Thundikandy and Anuradha Kanakath and Bala Murugan and R Vedhanayaki and Lyndell Lim and Eric Suhler and Hassan Al-Dhibi and Thuy Doan and Nisha Acharya and First-line Group},
  title = {Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.},
  abstract = {<p>This subanalysis from the First-line Antimetabolites as Steroid-sparing Treatment Trial found no significant difference in the time to achieve a corticosteroid-sparing dosage of prednisone for patients with noninfectious uveitis treated with methotrexate versus mycophenolate mofetil.</p>
},
  year = {2022},
  journal = {Ophthalmology},
  month = {2022 Jan 24},
  issn = {1549-4713},
  doi = {10.1016/j.ophtha.2022.01.020},
  language = {eng},
}